skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Products

Show More

Show More

21 Total results for product and free and sample content found

Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 28 Jul 2022

Profitability Assessment of Branded Generic Inhalers

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deals

In Vivo

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

By Dorothee Schramm and Katie von der Weid 27 Nov 2020

effective-relief

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

Topic Coronavirus Business Strategies Deals

Generics Bulletin

Biocon Biologics Gets True North Investment

By Vibha Ravi 27 Nov 2020

Biocon_Biologics_Gets_True_North_Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic Deals Strategy

Generics Bulletin

Pfizer Reports 80% Biosimilars Growth In Q3

By Akriti Seth 17 Nov 2020

pfizer biosimilars growth

Pfizer has reported 80% growth in its global biosimilars business for the third quarter of 2020, on the back of recent oncology launches. Though the company’s sterile injectables saw a slight drop in business, Pfizer’s biopharma business saw 4% growth.

Topic Coronavirus Biosimilars Deals

Pink Sheet, Scrip, In Vivo

Gene Therapy eBook

21 Aug 2020

Gene Therapy eBook

Keep up with advances in the critically important, emerging area of gene therapy. This transformative new category of medicines has the potential to treat more diseases – including complex and rare diseases – with longer-lasting effects than traditional medicines.

Topic Research & Development Deals

Generics Bulletin

Sun Finds US ‘Challenging’

By Penelope MacRae 17 Feb 2020

Flags_USA_India

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic Deals

Scrip

J.P. Morgan Conference Updates

By Mandy Jackson 22 Jan 2020

JP_Morgan_Notebook_Day_1

Updates and coverage of the 2020 J.P. Morgan Healthcare Conference in San Francisco.

Topic Business Strategies Deals Launches Reimbursement

Medtech Insight

Recipharm Boosts Inhalation And Injectables Manufacturing By Acquiring UK's Consort Medical

By Marion Webb 20 Nov 2019

Article

Sweden's Recipharm has agreed to buy UK-based Consort Medical for £505m ($652m) to become a leading inhalation-device company and top five global CDMO.

Topic Deals

Generics Bulletin

Lupin Offloads Kyowa For $525m But Not Exiting Japan

By Vibha Ravi 13 Nov 2019

Analysis

Lupin plans to invest in acquisitions and organic growth in the US and India after selling Japanese subsidiary Kyowa Pharma for an enterprise value of around $525m to Japan private equity group Unison Capital. But the Indian firm stresses it is not exiting Japan and will continue to look for marketing partnerships.

Topic Deals Strategy

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: